• Nachrichtendetail
• 

13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS

	Name	WKN	Börse	Kurs	Datum/Zeit	Diff.	Diff. %	Geld	Brief	Erster	Schluss
	SANOFI SA INHABER EO 2	920657	Xetra	90,550	04.06.24 16:52:04	+0,500	+0,56%	90,490	90,540	90,060	90,050
	REGENERON PHARMAC.DL-,001	881535	Frankfurt	903,200	04.06.24 08:06:02	-6,000	-0,66%	912,600	917,800	903,200	909,200